WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and Training

Tuesday, March 2, 2010 Corporate News
Email Print This Page Comment
Font : A-A+

SHANGHAI, March 1 WuXi PharmaTech (Cayman)Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical deviceresearch and development outsourcing company with operations in China and theUnited States, today announced it has reached an agreement with Johnson &Johnson Pharmaceutical Research & Development, a division of JanssenPharmaceutica N.V. (JANSSEN), to collaborate in the area of preclinicalservices.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Under the agreement, WuXi PharmaTech will become a provider of toxicologyand other non-clinical services to JANSSEN. In addition, JANSSEN will providetraining and other services, reimbursed by WuXi, to establish the GLP qualitysystem and technical capabilities to meet the international standards atWuXi's toxicology facility in Suzhou, China.

Construction of this facility, the largest in China with 314,000 squarefeet of space, was completed at the end of 2008. In 2009, the company hired amanagement team with extensive international experience and made substantialprogress in training an initial staff of technicians to perform GLP services.The facility is currently conducting non-GLP toxicology services, as well asclient-sponsored GLP validation studies to demonstrate our growingcapabilities. The company remains on target to begin offering GLP toxicologystudies by mid-2010.

Commenting on the agreement, Dr. Ge Li, Chairman and Chief ExecutiveOfficer of WuXi PharmaTech, said, "We are pleased to establish this newpartnership with JANSSEN, which builds on our existing agreement to providethem with integrated pharmaceutical R&D services. We believe that China, withits high-quality scientific talent and favorable cost structure, is destinedto become a major center for toxicology services over the next decade. We aimto become a leading provider of these services and to add toxicology to WuXi'sbroad, integrated platform of laboratory and preclinical services."For more information, please contact: Ronald Aldridge (for investors) Director of Investor Relations Tel: +1-201-585-2048 Email: ir@wuxiapptec.com Stephanie Liu (for the media) WuXi PharmaTech (Cayman) Inc. Tel: +86-21-5046-4362 Email: pr@wuxiapptec.com

SOURCE WuXi PharmaTech (Cayman) Inc.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook